# Neowise Biotechnology

Source: https://onco.cc/companies/neowise-biotechnology/  
OnCo record `neowise-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neowise Biotechnology is a Suzhou company making TCR-T cell therapies, a patient's own T cells given a receptor that recognises a marker inside cancer cells, for solid tumours. Its first product targets PRAME and a second targets a KRAS mutation.

## Summary

Neowise Biotechnology (Suzhou) Co., Ltd. was registered in Suzhou in September 2020, according to the company, by returnee scientists and develops TCR-T cell therapies for solid tumours. It has built a target and TCR discovery and validation platform and a database of target-TCR pairs (more than 7,000 by 2023, by its own count), holds patents on TCRs recognising PRAME and KRAS mutations, and operates a 3,500 square metre GMP pilot facility. Its company timeline lists an angel round of tens of millions of yuan in 2020, a Series A of nearly CNY 100 million in 2021 and a Series A+ of nearly CNY 200 million in 2023. Its first registered cancer trial, NCT07266298, a phase 1 dose-escalation study of NW-101C, PRAME-targeted TCR-T cells, in advanced solid tumours in Beijing, was posted on ClinicalTrials.gov in December 2025; a second product, NW-301V, TCR-T cells for solid tumours with the KRAS G12V mutation, entered the registry in October 2026 (NCT07875920), listing pancreatic, colorectal and lung adenocarcinoma.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Neowise Biotechnology (Suzhou) Co., Ltd.; 新景智源生物科技
- HQ: Suzhou
- Type: cell-therapy
- Website: https://www.neowisebio.com/

## Notes

- Facts are from the company's Chinese-language home page timeline, read on 29 October 2026; amounts are approximate as stated ('near'). Investor names not given.

## Sources

- Official website: https://www.neowisebio.com/
- ClinicalTrials.gov: phase 1 trial of NW-101C (NCT07266298): https://clinicaltrials.gov/study/NCT07266298
- ClinicalTrials.gov: phase 1 trial of NW-301V in KRAS G12V solid tumours (NCT07875920): https://clinicaltrials.gov/study/NCT07875920

## Connected records

- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [KRAS](https://onco.cc/targets/kras/), [PRAME](https://onco.cc/targets/prame/)

---
JSON: https://onco.cc/api/v1/entities/neowise-biotechnology.json